What is the evidence comparing tirzepatide and semaglutide in patients with obesity and diabetes (Medscape AI)

https://www.medscape.com/ai-search?query=What%20is%20the%20evidence%20comparing%20tirzepatide%20and%20semaglutide%20in%20patients%20with%20obesity%20and%20diabetes&ecd=wnl_tp10_daily_260126_MSCPEDIT_etid8057130&uac=148436CN&impID=8057130 Both tirzepatide and semaglutide—agents targeting incretin pathways—have been directly compared in patients with obesity and type 2 diabetes to assess differences in glycemic control and weight loss.